<DOC>
	<DOCNO>NCT01961908</DOCNO>
	<brief_summary>This study phase 2 , open-label extension study 12 mg Proellex 2 treatment cycle , 16 week active dosing period . Endometriosis pain , dysmenorrhea , non-menstrual pelvic pain dyspareunia ( BBSS ) well use pain medication , vaginal bleeding intensity record use electronic diary Visual Analog Scale ( VAS ) pain assessment utilized . All subject complete Off-Drug Interval ( ODI ) prior start treatment . Visit 1 schedule within week next expect menses ( +/- 2 day ) , follow off-drug interval . Subjects receive 2 cycle treatment separate off-drug interval ( ODI ) , follow menses return . During follow-up period subject continue record study information electronic diary . The final follow-up visit schedule blood flow stop .</brief_summary>
	<brief_title>Open-Label Extension Study ZPE-202</brief_title>
	<detailed_description />
	<mesh_term>Endometriosis</mesh_term>
	<criteria>Successful completion protocol ZPE202 , subject withdraw ZPE202 lack efficacy completion least 28 day doubleblind treatment ( Visit 3 ) Agreement attempt become pregnant trial Women childbearing potential must willing use doublebarrier contraception study 30 day discontinuation study medication . Acceptable doublebarrier method : male condom spermicide ; male condom diaphragm ; diaphragm contain spermicide plus additional intravaginal spermicide Has negative pregnancy test Visit 1 Is available treatment followup visit Subject pregnant lactating attempt expect become pregnant 67 month study period Concurrent use testosterone , progestin , androgen , estrogen , anabolic steroid , dehydroepiandrosterone ( DHEA ) hormonal product least 2 week prior Visit 1 . Presence intramural fibroid impact endometrial stripe , submucosal fibroid ( size ) , endometrial polyp . Subserosal intramural fibroid impact endometrial stripe acceptable . Presence endometrioma ( ) Present history condition cause nonendometriosis relate dyspareunia ( e.g . vulvar vestibulitis ) . Past present history thrombophlebitis thromboembolic disorder . Known suspect carcinoma breast reproductive organ . Cervical dysplasia classify Atypical Squamous Cells Undetermined Significance ( ASCUS ) associate highrisk human papilloma virus ( HPV ) Low/High Grade Squamous Intraepithelial Lesion ( LGSIL HGSIL ) . Known active infection HIV , Hepatitis A , B C. Endometrial stripe â‰¥18 mm thickness Visit 1 . Subject currently take cimetidine spironolactone . Clinically significant abnormal finding screen examination laboratory assessment condition opinion investigator would interfere participant 's ability comply study instruction endanger participant take part study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>47 Years</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>